Acute myeloid leukemia from diagnosis to bone marrow transplantation: Experience from a single centre

B. Gamberi, G. Bandini, G. Visani, G. Rosti, A. Cenacchi, M. R. Motta, F. Fruet, E. Calori, S. Rizzi, P. Tosi, A. Belardinelli, E. Barbieri, R. Conte, S. Tura

Research output: Contribution to journalArticlepeer-review


We analysed the use of allogeneic bone marrow transplantation (BMT) in the treatment of acute myelogenous leukemia (AML). We evaluated 271 adult patients with newly diagnosed AML treated here between 1983 and 1992; 113 patients (42%) were eligible for BMT because of their age (<45 years until 1986 and <50 years later). Of these, HLA typing was performed on 81 patients (72%); 32 patients were not typed (19 had no sibling, 8 had a primary refractory leukemia, 3 died during induction, 1 had important previous toxicity and for one patient there was no recorded reason). Of the 81 typed, 36 patients (44.4%) were found to have an HLA-matched sibling donor and 21 (25%) underwent BMT (8% of the total population); 15 patients did not undergo BMT (6 relapsed before transplantation and did not obtain a second remission, 3 declined the procedure, 1 died during induction, 1 had positive MLR, 1 had positive MLR and HCV hepatitis, 1 was a drug addict with HCV hepatitis, 1 had previous organ toxicity, 1 was psychotic). These data show that only a small fraction of unselected patients with AML can undergo BMT. Such findings make the comparison of BMT with other types of post-remission therapy more complex.

Original languageEnglish
Pages (from-to)69-72
Number of pages4
JournalBone Marrow Transplantation
Issue number1
Publication statusPublished - 1994

ASJC Scopus subject areas

  • Hematology
  • Transplantation


Dive into the research topics of 'Acute myeloid leukemia from diagnosis to bone marrow transplantation: Experience from a single centre'. Together they form a unique fingerprint.

Cite this